Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
HIV
Biotech
Merck's HIV combo matches Gilead's Biktarvy in phase 3 test
Merck reported another phase 3 win for islatravir, advancing its efforts to establish the molecule as a new anchor treatment for HIV.
Nick Paul Taylor
Nov 19, 2025 8:10am
NIH cuts disrupted hundreds of clinical trials, study finds
Nov 17, 2025 11:00am
Gilead settles on twice-yearly treatment partner for lenacapavir
Oct 30, 2025 6:37pm
Merck wades deeper into HIV PrEP waters with pair of trials
Jul 14, 2025 1:12pm
Fierce Healthcare
Judge sides with states, blocking HHS reorg and mass layoffs
Jul 1, 2025 3:30pm
FDA slaps clinical hold on multiple Gilead HIV trials
Jun 10, 2025 10:48am